Harvard Bioscience Expects FY23 Revenues Of $116M-$120M; Consensus $120.76M
Portfolio Pulse from Benzinga Newsdesk
Harvard Bioscience forecasts its FY23 revenues to be between $116M-$120M, slightly below the consensus estimate of $120.76M. The company anticipates a 4% headwind from discontinued products.
August 08, 2023 | 11:38 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Harvard Bioscience's FY23 revenue forecast is slightly below the consensus estimate, which could potentially impact the company's stock negatively in the short term.
Harvard Bioscience's FY23 revenue forecast is slightly below the consensus estimate. This could lead to a negative sentiment among investors, potentially causing a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100